Verona Pharma PLC (VRNA)
13.00
-0.36
(-2.69%)
USD |
NASDAQ |
May 17, 16:00
13.03
+0.03
(+0.23%)
After-Hours: 20:00
Verona Pharma SG&A Expense (Quarterly): 20.43M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 20.43M |
| December 31, 2023 | 14.97M |
| September 30, 2023 | 13.35M |
| June 30, 2023 | 12.44M |
| March 31, 2023 | 9.589M |
| December 31, 2022 | 8.323M |
| September 30, 2022 | 5.29M |
| June 30, 2022 | 5.526M |
| March 31, 2022 | 7.44M |
| December 31, 2021 | 5.757M |
| September 30, 2021 | 10.88M |
| June 30, 2021 | 7.985M |
| March 31, 2021 | 9.282M |
| December 31, 2020 | 11.45M |
| September 30, 2020 | 8.284M |
| June 30, 2020 | 3.172M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.862M |
| December 31, 2019 | 2.437M |
| September 30, 2019 | 2.424M |
| June 30, 2019 | 2.699M |
| March 31, 2019 | 2.388M |
| December 31, 2018 | 1.931M |
| September 30, 2018 | 1.846M |
| June 30, 2018 | 2.317M |
| March 31, 2018 | 2.043M |
| December 31, 2017 | 1.343M |
| September 30, 2017 | 2.733M |
| June 30, 2017 | 2.562M |
| March 31, 2017 | 1.288M |
| December 31, 2016 | 1.034M |
| September 30, 2016 | 0.9797M |
| June 30, 2016 | 0.4678M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.424M
Minimum
Sep 2019
20.43M
Maximum
Mar 2024
8.430M
Average
8.134M
Median
SG&A Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 1.597M |
| TC BioPharm (Holdings) PLC | -- |
| Bicycle Therapeutics PLC | 16.45M |
| Adaptimmune Therapeutics PLC | 19.73M |